BeiGene, Ltd. (ONC)vsQ32 Bio Inc (QTTB)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
QTTB
Q32 Bio Inc
$7.25
-0.68%
HEALTHCARE · Cap: $98.89M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 9843% more annual revenue ($5.34B vs $53.74M). QTTB leads profitability with a 55.5% profit margin vs 5.4%. QTTB trades at a lower P/E of 2.8x. QTTB earns a higher WallStSmart Score of 60/100 (C).
ONC
Hold42
out of 100
Grade: D
QTTB
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Margin of Safety
+76.7%
Fair Value
$16.46
Current Price
$7.25
$9.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Every $100 of equity generates 125 in profit
Keeps 56 of every $100 in revenue as profit
Strong operational efficiency at 85.4%
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : QTTB
The strongest argument for QTTB centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 55.5% and operating margin at 85.4%.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : QTTB
The primary concerns for QTTB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while QTTB is a value play — different risk/reward profiles.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
QTTB scores higher overall (60/100 vs 42/100), backed by strong 55.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Q32 Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Q32 Bio Inc. is a pioneering biotechnology firm focused on developing innovative antibody-based therapies to address autoimmune diseases and enhance immune responses. Utilizing its proprietary technology platform, the company is advancing a robust pipeline of treatments designed to restore immune system balance. Backed by a seasoned management team and strategic collaborations, Q32 Bio is well-positioned to leverage its scientific expertise to meet significant unmet medical needs, thereby driving transformative advancements in healthcare and creating value for shareholders through sustained research and development initiatives.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?